Viroclinics Biosciences, Rotterdam, the Netherlands, a leading virology contract research organization, has announced that it has acquired DDL Diagnostic Laboratory, Rijswijk, the Netherlands, a leading diagnostic solutions provider. The transaction enhances the combined group’s leading global position in antiviral and vaccine testing and will serve to accelerate their ambitious growth strategy.
Viroclinics was founded in 2001 and specializes in the fields of virology and global logistics services. DDL was founded in 1994 and is an expert laboratory in advanced (molecular) diagnostic testing. Both companies operate globally, serving leading biopharmaceutical companies active in the field of microbial vaccines and antivirals.

Viroclinics is the global leader in influenza and other viral targets, such as respiratory syncytial virus and polio, while DDL also specializes in the fields of hepatitis and human papilloma virus. The combined organization will operate from four testing laboratories located in Europe and China, with access to a global network of processing facilities across 20 countries to coordinate sample collection in strategic regions worldwide to serve global trials.

“By joining with DDL, we will enhance Viroclinics’ leading position as a specialized contract research organization, adding to our service offering, capacity, and geographic presence,” says Bob van Gemen, PhD, CEO of Viroclinics Biosciences, who will serve as CEO of the combined organization. “I look forward to working with the DDL team and continuing to build on our leading global position as a virology CRO.”

For further information, visit Viroclinics Biosciences.